Skip to content
Open in App
Moderna logo

Moderna

web2

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States,...

Symbol · MRNAUS
Company profile

About

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

INTerpath 001 Phase 3 met melanoma efficacy endpoints

KEY STEP

Moderna and Merck announced that intismeran autogene plus Keytruda met the primary recurrence free survival endpoint and a key secondary distant metastasis free survival endpoint in the Phase 3 INTerpath 001 trial for completely resected stage IIB through IV melanoma.

Roadmap reference

FDA approved mFLUSIVA for adults age 50 and older

KEY STEP

Moderna announced FDA approval of mFLUSIVA for seasonal influenza prevention in adults age 50 and older, making it the company’s fifth approved product globally and the first mRNA based seasonal flu vaccine approved in the United States.

Roadmap reference

Moderna completed $3.0 billion convertible note offering

KEY STEP

Moderna completed a $3.0 billion aggregate principal amount offering of 0.00% convertible senior notes due 2032 after the initial purchasers exercised their $400 million option in full. The company said remaining net proceeds could support general corporate purposes, including oncology growth and debt repayment.

Roadmap reference
People

Company team

SJ

Sandra J. Horning

Independent Director

Company leadership profile.

EG

Elizabeth G. Nabel

Independent Director

Company leadership profile.

NB

Noubar B. Afeyan

Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board

Company leadership profile.

SB

Stéphane Bancel

CEO & Director

Company leadership profile.

DE

Darin Edwards

Executive Director

Company leadership profile.

JW

Jack W. Szostak

Chairman of Scientific Advisory Board

Company leadership profile.

FN

Francois Nader

Independent Non Executive Director

Company leadership profile.

EE

Elizabeth Edith Tallett

Independent Director

Company leadership profile.

RS

Robert S. Langer

Member of Scientific Advisory Board

Company leadership profile.

UH

Ulrich H. von Andrian-Werburg

Member of Scientific Advisory Board

Company leadership profile.

JG

John G. Aunins

Member of Technology Advisory Board

Company leadership profile.

SA

Scott A. Canute

Member of Technology Advisory Board

Company leadership profile.

FE

Fred E. Regnier

Member of Technology Advisory Board

Company leadership profile.

JR

James R. Swartz

Member of Technology Advisory Board

Company leadership profile.

RC

Richard C. Willson

Member of Technology Advisory Board

Company leadership profile.

MJ

Melissa J. Moore

Member of Scientific Advisory Board

Company leadership profile.

RE

Ron Eydelloth

Member of Scientific Advisory Board

Company leadership profile.

RG

Rachel Green

Member of Scientific Advisory Board

Company leadership profile.

MD

Michael Diamond

Member of Scientific Advisory Board

Company leadership profile.

PT

Paula T. Hammond

Member of Scientific Advisory Board

Company leadership profile.

RW

Ralph Weissleder

Member of Scientific Advisory Board

Company leadership profile.

DM

David Mark Rubenstein

Independent Director

Company leadership profile.

SA

Shah Abbas Hussain

Independent Director

Company leadership profile.

MR

Michael R. McDonnell

Director

Company leadership profile.

Expert coverage

2 experts evaluated Moderna.

Orbitrum research

Experts evaluating Moderna

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment